Photo by andreacaramello from unsplash
Key Points • Crystallization studies map the binding of glenzocimab to the site of dimerization in the D2 domain of GPVI.• Glenzocimab inhibits GPVI interactions with CRP, collagen, and fibrin… Click to show full abstract
Key Points • Crystallization studies map the binding of glenzocimab to the site of dimerization in the D2 domain of GPVI.• Glenzocimab inhibits GPVI interactions with CRP, collagen, and fibrin by loss of dimerization, conformational changes, and steric hindrance.
Keywords:
glenzocimab novel;
glenzocimab;
gpvi glenzocimab;
platelet gpvi;
targeting platelet
Journal Title: Blood Advances
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Blood Advances
Year Published: 2022
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!